A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast

NCT05267327 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

1500

Enrollment

OTHER

Sponsor class

Conditions

The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks

Interventions

OTHER: Verzenios

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborators

[object Object]